Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutics for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. Its lead drug candidate, Piclidenoson, has completed Phase III clinical trials for psoriasis. The company’s pipeline includes Piclidenoson, Namodenoson, and CF602, which aim to modulate immune responses and target specific disease pathways. These drug candidates are...
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutics for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. Its lead drug candidate, Piclidenoson, has completed Phase III clinical trials for psoriasis. The company’s pipeline includes Piclidenoson, Namodenoson, and CF602, which aim to modulate immune responses and target specific disease pathways. These drug candidates are based on the company’s proprietary technology platform that targets the A3 adenosine receptor, involved in regulating inflammation and immune responses. Can-Fite works with research institutions and clinical centers to advance its product candidates through clinical development.
Business Segments
The company operates primarily in the biotechnology sector, focusing on the development of therapeutic products for cancer and inflammatory diseases. Its business segments are oncology and inflammatory diseases, where it develops a range of small molecule drugs targeting specific receptors involved in disease progression.
Oncology
This segment is focused on developing drugs that target cancer cells while minimizing damage to healthy tissues. The lead product candidate, Piclidenoson, is currently undergoing clinical trials for various cancer indications. The company aims to establish a strong presence in the oncology market by advancing its product candidates through clinical trials and seeking regulatory approvals for commercialization.
Inflammatory diseases
This segment is focused on developing treatments for inflammatory diseases. Namodenoson, another lead product candidate, is being investigated for its potential to treat conditions such as psoriasis and liver diseases. The company’s approach involves leveraging its proprietary technology platform to create therapies that can effectively modulate the immune response and provide relief to patients suffering from chronic inflammatory conditions.
Business Strategy
The company’s business strategy focuses on developing and commercializing innovative therapeutic products to address unmet medical needs. The main objective is to advance its lead product candidates through clinical trials to obtain regulatory approvals. By utilizing its proprietary technology platform, the company aims to build a diverse pipeline of drug candidates targeting specific receptors linked to various diseases.
A key element of the strategy is forming strategic partnerships and collaborations with biotechnology firms, research institutions, and clinical centers. These alliances are designed to enhance research capabilities, broaden networks, and accelerate the clinical development of product candidates. Collaborating with established organizations helps the company access additional resources and expertise.
The company also prioritizes maintaining a strong intellectual property portfolio to protect its innovations and secure a competitive edge. By obtaining patents for its product candidates and technologies, the company aims to safeguard its investments and strengthen its market position. This strategy, along with active engagement with regulatory agencies, is intended to streamline the approval process and ensure compliance with industry standards.
Products and Services
The company’s primary products are its lead drug candidates, which are designed to treat cancer and inflammatory diseases. The most advanced product candidate, Piclidenoson, is being developed for multiple cancer indications. This drug candidate is based on the company’s proprietary technology platform and targets the A3 adenosine receptor, which plays a crucial role in regulating immune responses and tumor growth.
Namodenoson is another significant product candidate in the company’s pipeline, aimed at treating inflammatory diseases such as psoriasis and liver conditions. The company is conducting clinical trials to evaluate the safety and efficacy of Namodenoson, with the objective of bringing this innovative therapy to market. CF602 is an additional drug candidate that is currently under development. The company is focused on advancing this candidate through clinical trials, with the aim of addressing specific therapeutic needs in the oncology space.
Seasonality
The company does not experience significant seasonality in its operations. The biotechnology sector, particularly in drug development, is characterized by long development timelines and regulatory processes that are not influenced by seasonal fluctuations. The company’s research and development activities, clinical trials, and regulatory submissions are conducted year-round, ensuring a continuous focus on advancing its product candidates.
Customers
The company serves a diverse range of customers, primarily in the healthcare and pharmaceutical sectors. Its customers include healthcare providers, research institutions, and pharmaceutical companies that are involved in the development and commercialization of therapeutic products. The company’s focus on innovative drug development positions it to meet the needs of various stakeholders in the healthcare ecosystem.
Marketing/Distribution Channels
The company employs a strategic approach to marketing and distribution that focuses on building partnerships with healthcare providers and pharmaceutical companies. The company’s marketing efforts are centered around educating stakeholders about the benefits and potential of its product candidates. The company engages in direct marketing efforts, as well as collaborations with established partners to enhance its market presence. By leveraging the expertise of its partners, the company aims to effectively reach its target audiences and facilitate the successful commercialization of its product candidates.
History
The company was founded in 1994. The company was incorporated in 1994. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in 2001.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
